GlassScriptPhysician profile
Anita Khandelwal
NPI 1518988047
$6,432.70
in general payments reported to CMS, 2019-2025
33 companies · $886 in 2025
The $886 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $814 · 2021: $1,191 · 2022: $1,063 · 2023: $1,068 · 2024: $1,221 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,113 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,113.40 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,676.30 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $906.79 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $723.44 | 2020-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $569.02 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $349.97 | 2021-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.33 | 2020-2023 | Jardiance |
| Pfizer INC. | $268.84 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $249.71 | 2020-2022 | |
| Dexcom, INC. | $207.47 | 2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $163.14 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $132.47 | 2019-2021 | |
| Ardelyx, INC. | $121.66 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $120.00 | 2025 | Rezdiffra |
| Genzyme Corporation | $120.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $61.65 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $56.18 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $53.39 | 2024 | Eohilia |
| Amarin Pharma, INC. | $34.09 | 2021-2022 | |
| Nevro Corp. | $30.44 | 2022 | |
| Sanofi Pasteur INC. | $29.39 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $25.95 | 2025 | Gemtesa |
| Daiichi Sankyo INC. | $24.41 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.01 | 2023 | |
| Smith+Nephew, INC. | $21.90 | 2019 | |
| Seqirus USA INC | $21.85 | 2025 | Fluad, Flucelvax |
| Biohaven Pharmaceuticals, INC. | $19.41 | 2021 | |
| Genentech USA, INC. | $19.10 | 2020 | |
| Phathom Pharmaceuticals, INC. | $16.68 | 2023 | Voquezna |
| Horizon Therapeutics Plc | $16.01 | 2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $15.75 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.23 | 2020 | |
| Radius Health, INC. | $14.72 | 2023 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anita Khandelwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.